PRE-MARKET INDIAN STOCKS NEWS: Q2 earnings from HDFC Bank, ICICI Bank, Axis Bank and Yes Bank; India to cut prices of up to 137 cancer drugs

The quarterly cluster of India's large private-sector banks reporting together gives a cleaner read on system trends than any single print: the recurring split is between net interest income growth, which has been the cycle's support, and the twin pressures of margin compression as deposit costs reprice upward and normalising credit costs after an unusually benign provisioning phase. On past occasions, beats and misses of this size have rotated relative performance within the bank-heavy Nifty rather than moved the broader tape. Two items sit outside the routine print. The Yes Bank result is a headline artifact: the reported profit excludes a court decision reversing a legacy bond write-off, and a pro-forma loss of that scale, with remedies still being weighed, leaves the accounting outcome and the capital treatment unresolved until the bank states its course. The leadership transition at HDFC Bank is the more structural thread, with a deputy's exit bracketing the incoming chief executive's start; successions at institutions of that size have tended to sharpen focus on strategy continuity and integration costs rather than the quarter itself. The cancer-drug price cap follows an established Indian pattern of trade-margin regulation: the direct hit concentrates in oncology-exposed domestic pharma revenue, while distributors and hospitals absorb part of the compression, and prior rounds have seen volume gains offset only a fraction of the price cut. The follow-ons are management commentary on margins and deposit pricing from the bank calls, Yes Bank's stated legal and provisioning response, and which manufacturers are most exposed to the capped molecules.